Trial reportJournal for immunotherapy of cancer2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Trial report in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review.International journal of clinical oncology · 2025Pooled it
- Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.Cancer immunology, immunotherapy : CII · 2025Trial
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- Vaccines as treatment for melanoma: an update review.Frontiers in immunology · 2026Review
- Characterisation of tumor-infiltrating gamma-delta T cells in human colorectal cancer with MHC-I loss.Clinical & translational immunology · 2026Article
- FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.Cancers · 2025Review
- Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization.NPJ vaccines · 2025Article
- Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies.Cell reports. Medicine · 2025Article
- Plant-Derived Immunomodulatory Nanoadjuvants for Cancer Vaccines: Current Status and Future Opportunities.Vaccines · 2025Review
- Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice.Scientific reports · 2025Article
- Single-cell sequencing unveils extensive intratumoral heterogeneity of cancer/testis antigen expression in melanoma and lung cancer.Journal for immunotherapy of cancer · 2024Article
- The quest for nanoparticle-powered vaccines in cancer immunotherapy.Journal of nanobiotechnology · 2024Review
- Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens.Frontiers in immunology · 2024Article
- The Matrix-M™ adjuvant: A critical component of vaccines for the 21Human vaccines & immunotherapeutics · 2023Review
- Review
- Adjuvant activity of tubeimosides by mediating the local immune microenvironment.Frontiers in immunology · 2023Article
- A genetically engineered, stem-cell-derived cellular vaccine.Cell reports. Medicine · 2022Article
- Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Current Prospects in Peptide-Based Subunit Nanovaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity.Science immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 20 institutions in 4 countries.
Funding
Abstract
backgroundTo compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence.
methodsParticipants with resected stage IIc, IIIb, IIIc and IV melanoma expressing NY-ESO-1 were randomized to treatment with three doses of NY-ESO-1/ISCOMATRIX or ISCOMATRIX adjuvant administered intramuscularly at 4-week intervals, followed by a further dose at 6 months. Primary endpoint was the proportion free of relapse at 18 months in the intention-to-treat (ITT) population and two per-protocol populations. Secondary endpoints included relapse-free survival (RFS) and overall survival (OS), safety and NY-ESO-1 immunity.
resultsThe ITT population comprised 110 participants, with 56 randomized to NY-ESO-1/ISCOMATRIX and 54 to ISCOMATRIX alone. No significant toxicities were observed. There were no differences between the study arms in relapses at 18 months or for median time to relapse; 139 vs 176 days (p=0.296), or relapse rate, 27 (48.2%) vs 26 (48.1%) (HR 0.913; 95% CI 0.402 to 2.231), respectively. RFS and OS were similar between the study arms. Vaccine recipients developed strong positive antibody responses to NY-ESO-1 (p≤0.0001) and NY-ESO-1-specific CD4
conclusionsThe vaccine was well tolerated, however, despite inducing antigen-specific immunity, it did not affect survival endpoints. Immune escape through the downregulation of NY-ESO-1 and/or HLA class I molecules on tumor may have contributed to relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.